[go: up one dir, main page]

SMT202100459T1 - Azasetron per l’uso nel trattamento della perdita dell’udito - Google Patents

Azasetron per l’uso nel trattamento della perdita dell’udito

Info

Publication number
SMT202100459T1
SMT202100459T1 SM20210459T SMT202100459T SMT202100459T1 SM T202100459 T1 SMT202100459 T1 SM T202100459T1 SM 20210459 T SM20210459 T SM 20210459T SM T202100459 T SMT202100459 T SM T202100459T SM T202100459 T1 SMT202100459 T1 SM T202100459T1
Authority
SM
San Marino
Prior art keywords
azasetron
treatment
hearing loss
hearing
loss
Prior art date
Application number
SM20210459T
Other languages
English (en)
Inventor
Jonas Dyhrfjeld-Johnsen
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Publication of SMT202100459T1 publication Critical patent/SMT202100459T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SM20210459T 2015-05-18 2016-05-18 Azasetron per l’uso nel trattamento della perdita dell’udito SMT202100459T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562163177P 2015-05-18 2015-05-18
EP15167992 2015-05-18
EP16725074.5A EP3297628B1 (en) 2015-05-18 2016-05-18 Azasetron for use in the treatment of hearing loss
PCT/EP2016/061119 WO2016184900A1 (en) 2015-05-18 2016-05-18 Calcineurin inhibitors of the setron family for the treatment of hearing loss

Publications (1)

Publication Number Publication Date
SMT202100459T1 true SMT202100459T1 (it) 2021-09-14

Family

ID=53199806

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210459T SMT202100459T1 (it) 2015-05-18 2016-05-18 Azasetron per l’uso nel trattamento della perdita dell’udito

Country Status (13)

Country Link
US (2) US11433077B2 (it)
EP (2) EP3297628B1 (it)
JP (2) JP6994765B2 (it)
CN (1) CN107847489B (it)
CY (1) CY1124406T1 (it)
ES (1) ES2882602T3 (it)
HU (1) HUE056138T2 (it)
PL (1) PL3297628T3 (it)
PT (1) PT3297628T (it)
RS (1) RS62226B1 (it)
SI (1) SI3297628T1 (it)
SM (1) SMT202100459T1 (it)
WO (1) WO2016184900A1 (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056138T2 (hu) * 2015-05-18 2022-01-28 Sensorion Azasetron a halláskárosodás kezelésében való felhasználásra
HUE066000T2 (hu) * 2016-04-14 2024-06-28 Sensorion (+)-Azaszetron fül rendellenességek kezelésében történõ alkalmazásra
KR102429935B1 (ko) * 2016-04-14 2022-08-08 센소리온 귀 장애의 치료에 사용하기 위한 (+)-아자세트론
JP7044294B2 (ja) * 2017-09-21 2022-03-30 学校法人慶應義塾 音響外傷難聴モデル動物の作製用の音響暴露装置
WO2019136382A1 (en) 2018-01-05 2019-07-11 Laslo Olah Hearing aid and method for use of same
US11095992B2 (en) * 2018-01-05 2021-08-17 Texas Institute Of Science, Inc. Hearing aid and method for use of same
CN108309964B (zh) * 2018-04-04 2020-06-30 军事科学院军事医学研究院环境医学与作业医学研究所 二甲双胍在制备噪声性听力损失防治产品中的应用
WO2021014014A1 (en) 2019-07-25 2021-01-28 Sensorion Treatment and/or prevention of lesions in the central auditory nervous system
US20250170139A1 (en) * 2022-03-16 2025-05-29 Sensorion Azasetron for the treatment of sudden sensorineural hearing loss
WO2025008371A1 (en) 2023-07-03 2025-01-09 Sensorion Azasetron for the preservation of residual hearing following cochlear implantation
US12108220B1 (en) 2024-03-12 2024-10-01 Laslo Olah System for aiding hearing and method for use of same
US12262179B1 (en) 2024-03-12 2025-03-25 Laslo Olah Audiogram, system for aiding hearing, and method for use of same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
US20050014743A1 (en) * 2003-05-27 2005-01-20 Forest Laboratories, Inc. Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
TW200922544A (en) * 2007-09-12 2009-06-01 Merz Pharma Gmbh & Amp Co Kgaa Interval therapy for the treatment of tinnitus
BRPI0915770A2 (pt) 2008-07-14 2015-11-03 Otonomy Inc composição de modulação de apoptose de liberação controlada e métodos para o tratamento de distúrbios ótológicos
DE102009003232A1 (de) * 2009-05-19 2010-12-02 Federal-Mogul Burscheid Gmbh Gleitelement eines Verbrennungsmotors, insbesondere Kolbenring
JP5955767B2 (ja) * 2009-05-20 2016-07-20 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬
US10188695B2 (en) * 2012-02-23 2019-01-29 Sensorion Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
ES2785303T3 (es) 2012-07-16 2020-10-06 Univ Cornell Nicotinamida ribósido para tratar la pérdida auditiva
HUE056138T2 (hu) * 2015-05-18 2022-01-28 Sensorion Azasetron a halláskárosodás kezelésében való felhasználásra
HUE066000T2 (hu) * 2016-04-14 2024-06-28 Sensorion (+)-Azaszetron fül rendellenességek kezelésében történõ alkalmazásra

Also Published As

Publication number Publication date
JP6994765B2 (ja) 2022-02-10
CN107847489A (zh) 2018-03-27
US11433077B2 (en) 2022-09-06
JP2022028941A (ja) 2022-02-16
PL3297628T3 (pl) 2021-12-06
ES2882602T3 (es) 2021-12-02
SI3297628T1 (sl) 2021-10-29
CN107847489B (zh) 2021-09-17
US20220387438A1 (en) 2022-12-08
WO2016184900A1 (en) 2016-11-24
CY1124406T1 (el) 2022-07-22
EP3297628A1 (en) 2018-03-28
EP3297628B1 (en) 2021-06-09
PT3297628T (pt) 2021-08-16
US20180207167A1 (en) 2018-07-26
EP3909579A1 (en) 2021-11-17
JP2018522938A (ja) 2018-08-16
RS62226B1 (sr) 2021-09-30
HUE056138T2 (hu) 2022-01-28

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
PL3297628T3 (pl) Azasetron do stosowania w leczeniu niedosłuchu
EP3160405A4 (en) Treatment of the ear
GB201608885D0 (en) Treatment
GB201502137D0 (en) Treatment
GB201522243D0 (en) Treatment
IL251904A0 (en) Epilimod for use in the treatment of melanoma
GB2543540B (en) Decellularising tissue
IL266701A (en) An implant with several cavities
IL270701A (en) Neurotrophins for use in the treatment of hearing loss
GB201519450D0 (en) Novel treatment
IL253617A0 (en) Snekribirock for the treatment of leprosy
GB201508841D0 (en) Treatment
IL262305B (en) Azasterone for use in the treatment of disorders related to the ear
EP3323368A4 (en) TREATMENT TOOL
GB201503008D0 (en) Treatment
LT3297628T (lt) Azasetronas, skirtas naudoti klausos praradimo gydymui
GB201718985D0 (en) Treatment
GB201713650D0 (en) Treatment
GB201706955D0 (en) Treatment
GB201617107D0 (en) Treatment
GB2555225B (en) Hydrocarbon-contamination treatment unit
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment